The Experts below are selected from a list of 11844 Experts worldwide ranked by ideXlab platform

Syed S. Haqqie - One of the best experts on this subject based on the ideXlab platform.

  • METABOLIC AND SKELETAL EFFECTS OF LOW AND HIGH DOSES OF Calcium Acetate IN PATIENTS WITH PRETERMINAL CHRONIC RENAL FAILURE
    American Journal of Nephrology, 2002
    Co-Authors: Kenneth R. Phelps, Marc Stern, Alice Slingerland, Mahin Heravi, David S. Strogatz, Syed S. Haqqie
    Abstract:

    Background: Secondary hyperparathyroidism commonly evolves, as the glomerular filtration rate falls. The metabolic and skeletal effects of a possible remedy, Calcium Acetate, have n

  • Metabolic and skeletal effects of low and high doses of Calcium Acetate in patients with preterminal chronic renal failure.
    American journal of nephrology, 2002
    Co-Authors: Kenneth R. Phelps, Marc Stern, Alice Slingerland, Mahin Heravi, David S. Strogatz, Syed S. Haqqie
    Abstract:

    Secondary hyperparathyroidism commonly evolves, as the glomerular filtration rate falls. The metabolic and skeletal effects of a possible remedy, Calcium Acetate, have not been studied in patients with preterminal chronic renal failure. Men with a mean creatinine clearance of approximately 30 ml/min took Calcium Acetate for 24 weeks at doses which provided 507 or 1,521 mg Calcium/day with meals. Metabolic determinations were made at intervals of 4-8 weeks, and the bone mineral density (BMD) was measured at the beginning and at the end of the trial. The low-dose regimen produced no metabolic or skeletal effect. In subjects prescribed the high-dose regimen, the 24-hour urine phosphorus excretion fell from 0.53 mg/mg creatinine to values ranging from 0.34 to 0.41 mg/mg creatinine. The theoretical phosphorus threshold concentration rose by a maximum of 38.6%, and the serum phosphorus concentration did not change. The mean serum Calcium concentration rose by a maximum of 7.2%. The mean fractional changes in parathyroid hormone and 1,25-dihydroxyvitamin D concentrations ranged from -27.0 to -39.6% and from -5.0 to -20.3%, respectively. The BMD increased at L1, L3, and L4. Calcium Acetate prescribed to deliver 1,521 mg Calcium/day with meals reduced parathyroid hormone and 1,25-dihydroxyvitamin D concentrations and increased lumbar BMD in men with preterminal chronic renal failure. Copyright 2002 S. Karger AG, Basel

Kenneth R. Phelps - One of the best experts on this subject based on the ideXlab platform.

  • METABOLIC AND SKELETAL EFFECTS OF LOW AND HIGH DOSES OF Calcium Acetate IN PATIENTS WITH PRETERMINAL CHRONIC RENAL FAILURE
    American Journal of Nephrology, 2002
    Co-Authors: Kenneth R. Phelps, Marc Stern, Alice Slingerland, Mahin Heravi, David S. Strogatz, Syed S. Haqqie
    Abstract:

    Background: Secondary hyperparathyroidism commonly evolves, as the glomerular filtration rate falls. The metabolic and skeletal effects of a possible remedy, Calcium Acetate, have n

  • Metabolic and skeletal effects of low and high doses of Calcium Acetate in patients with preterminal chronic renal failure.
    American journal of nephrology, 2002
    Co-Authors: Kenneth R. Phelps, Marc Stern, Alice Slingerland, Mahin Heravi, David S. Strogatz, Syed S. Haqqie
    Abstract:

    Secondary hyperparathyroidism commonly evolves, as the glomerular filtration rate falls. The metabolic and skeletal effects of a possible remedy, Calcium Acetate, have not been studied in patients with preterminal chronic renal failure. Men with a mean creatinine clearance of approximately 30 ml/min took Calcium Acetate for 24 weeks at doses which provided 507 or 1,521 mg Calcium/day with meals. Metabolic determinations were made at intervals of 4-8 weeks, and the bone mineral density (BMD) was measured at the beginning and at the end of the trial. The low-dose regimen produced no metabolic or skeletal effect. In subjects prescribed the high-dose regimen, the 24-hour urine phosphorus excretion fell from 0.53 mg/mg creatinine to values ranging from 0.34 to 0.41 mg/mg creatinine. The theoretical phosphorus threshold concentration rose by a maximum of 38.6%, and the serum phosphorus concentration did not change. The mean serum Calcium concentration rose by a maximum of 7.2%. The mean fractional changes in parathyroid hormone and 1,25-dihydroxyvitamin D concentrations ranged from -27.0 to -39.6% and from -5.0 to -20.3%, respectively. The BMD increased at L1, L3, and L4. Calcium Acetate prescribed to deliver 1,521 mg Calcium/day with meals reduced parathyroid hormone and 1,25-dihydroxyvitamin D concentrations and increased lumbar BMD in men with preterminal chronic renal failure. Copyright 2002 S. Karger AG, Basel

T. V. Safronova - One of the best experts on this subject based on the ideXlab platform.

  • Calcium Phosphate Powder Synthesized from Calcium Acetate and Ammonium Hydrophosphate for Bioceramics Application
    Ceramics, 2018
    Co-Authors: T. V. Safronova, G. K. Kazakova, V.i. Putlayev, Yaroslav Filippov, Tatiana Shatalova, Evgeny A. Karpushkin, Dmitrii Larionov, Yury Shakhtarin
    Abstract:

    Calcium phosphate powder was synthesized at room temperature from aqueous solutions of ammonium hydrophosphate and Calcium Acetate without pH adjusting at constant Ca/P molar ratio 1.5. Phase composition of the as-synthesized powder depended on the precursors concentration: At 2.0 M of Calcium Acetate in the starting solution, poorly crystallized hydroxyapatite was formed, 0.125 M solution of Calcium Acetate afforded brushite, and the powders synthesized from 0.25–1.0 M Calcium Acetate solutions were mixtures of the mentioned phases. Firing at 1100 °C led to complete elimination of the reaction by-products, yet the phase composition of the annealed compacted samples was the following: When 2.0 M solution of Calcium Acetate was used, the obtained ceramics consisted of β-Ca3(PO4)2, whereas at 0.125 to 1.0 M of Calcium Acetate, the ceramics was a mixture of β-Ca3(PO4)2 and β-Ca2P2O7. Synthesized Calcium phosphate powders can be used as the powdered precursors for biocompatible bioresorbable composite ceramics production.

  • Calcium pyrophosphate powder for production of bioceramics synthesized from pyrophosphoric acid and Calcium Acetate
    Inorganic Materials: Applied Research, 2017
    Co-Authors: T. V. Safronova, Tatiana Shatalova, S A Kurbatova, A V Knotko, P V Yevdokimov, V I Putlyayev
    Abstract:

    Hydrated amorphous Calcium pyrophosphate powder was synthesized from an aqueous solution containing pyrophosphoric acid and Calcium Acetate with the addition of an aqueous solution of ammonia. A distinctive feature of the proposed synthesis consisted in the use of pyrophosphoric acid synthesized by treatment of a sodium pyrophosphate solution with ion exchange resin (H+ form). The phase composition of ceramic fabricated from the powder after the calcination at 600–1000°C was represented by β-Ca2P2O7. The synthesized powder can be recommended for the fabrication of porous biocompatible resorbable ceramic.

  • amorphous Calcium phosphate powder synthesized from Calcium Acetate and polyphosphoric acid for bioceramics application
    Ceramics International, 2017
    Co-Authors: T. V. Safronova, Tatiana Shatalova, V. I. Putlyaev, A V Knotko, E A Mukhin, P V Evdokimov, Ya Yu Filippov, A V Sidorov, Evgeny A. Karpushkin
    Abstract:

    Abstract Amorphous hydrated Calcium phosphate powder was synthesized at room temperature from aqueous solutions of polyphosphoric acid and Calcium Acetate with addition of ammonia water solution. Synthesized powder remains amorphous after heat in the temperature range 200–500 °C. Phase composition of powder and compacted powder samples after firing at 800 °C consists of Calcium polyphosphate (β-Ca(PO3)2), tromelite (Ca4P6O19) and Calcium pyrophosphate (β-Ca2P2O7). Synthesis of amorphous hydrated Calcium phosphate powder with the ion-exchange stage for preparing an aqueous solution of polyphosphoric acid can be recommended as a simple way of production of powdered precursor for biocompatible bioresorbable phosphate ceramics containing Calcium polyphosphate, tromelite and Calcium pyrophosphate.

  • Properties of Calcium phosphate powder synthesized from Calcium Acetate and sodium hydrophosphate
    Glass and Ceramics, 2011
    Co-Authors: T. V. Safronova, V. I. Putlyaev, A. V. Kuznetsov, N. A. Ketov, A. G. Veresov
    Abstract:

    The properties of powder synthesized from Calcium Acetate and sodium hydrophosphate with the ratio $$ \left[ {{\text{C}}{{\text{a}}^{{2 + }}}} \right]/\left[ {{\text{PO}}_4^{3 - }} \right] $$ of the starting reagents equal to 1 have been investigated. After synthesis brushite, monetite, and octaCalcium phosphate were found in the powder. A substantial mass loss, equal to 26%, on heating is due to not only the decomposition of the phases found but also the removal of the byproducts, consisting of sodium Acetate and acetic acid and present in the powder, of the reactions occurring when the solutions of the starting substances interact. After firing at temperatures above 900°C the phases β-Ca_2P = O_7, β-Ca_3(PO_4)_2,and Ca_10Na(PO_4)_7 are found in the samples.

  • Ceramics made from Calcium hydroxyapatite synthesized from Calcium Acetate and potassium hydrophosphate
    Glass and Ceramics, 2008
    Co-Authors: T. V. Safronova, S. A. Korneichuk, V. I. Putlyaev, O. V. Boitsova
    Abstract:

    The properties of hydroxyapatite powder synthesized from Calcium Acetate and potassium hydrophosphate and hydroxide were investigated. The associated reaction product (ARP), whose basic component is potassium Acetate, modifies the surface of the hydroxyapatite nanocrystals. The components of the ARP can play the role of a salt matrix by preventing coalescence of nanocrystallites and can also serve as a source for a sintering additive which is uniformly distributed due to adsorption during synthesis. A ceramic based on hydroxyapatite with a uniform microstructure and a maximum grain size of 300 nm was obtained by incorporation of sintering additives in the form of ARP at a temperature of 700°C. The ARP is the cause of different solid-phase processes and processes involving the liquid phase. The sites where these processes occur are the boundaries of the grains, which also restrains their growth.

David S. Strogatz - One of the best experts on this subject based on the ideXlab platform.

  • METABOLIC AND SKELETAL EFFECTS OF LOW AND HIGH DOSES OF Calcium Acetate IN PATIENTS WITH PRETERMINAL CHRONIC RENAL FAILURE
    American Journal of Nephrology, 2002
    Co-Authors: Kenneth R. Phelps, Marc Stern, Alice Slingerland, Mahin Heravi, David S. Strogatz, Syed S. Haqqie
    Abstract:

    Background: Secondary hyperparathyroidism commonly evolves, as the glomerular filtration rate falls. The metabolic and skeletal effects of a possible remedy, Calcium Acetate, have n

  • Metabolic and skeletal effects of low and high doses of Calcium Acetate in patients with preterminal chronic renal failure.
    American journal of nephrology, 2002
    Co-Authors: Kenneth R. Phelps, Marc Stern, Alice Slingerland, Mahin Heravi, David S. Strogatz, Syed S. Haqqie
    Abstract:

    Secondary hyperparathyroidism commonly evolves, as the glomerular filtration rate falls. The metabolic and skeletal effects of a possible remedy, Calcium Acetate, have not been studied in patients with preterminal chronic renal failure. Men with a mean creatinine clearance of approximately 30 ml/min took Calcium Acetate for 24 weeks at doses which provided 507 or 1,521 mg Calcium/day with meals. Metabolic determinations were made at intervals of 4-8 weeks, and the bone mineral density (BMD) was measured at the beginning and at the end of the trial. The low-dose regimen produced no metabolic or skeletal effect. In subjects prescribed the high-dose regimen, the 24-hour urine phosphorus excretion fell from 0.53 mg/mg creatinine to values ranging from 0.34 to 0.41 mg/mg creatinine. The theoretical phosphorus threshold concentration rose by a maximum of 38.6%, and the serum phosphorus concentration did not change. The mean serum Calcium concentration rose by a maximum of 7.2%. The mean fractional changes in parathyroid hormone and 1,25-dihydroxyvitamin D concentrations ranged from -27.0 to -39.6% and from -5.0 to -20.3%, respectively. The BMD increased at L1, L3, and L4. Calcium Acetate prescribed to deliver 1,521 mg Calcium/day with meals reduced parathyroid hormone and 1,25-dihydroxyvitamin D concentrations and increased lumbar BMD in men with preterminal chronic renal failure. Copyright 2002 S. Karger AG, Basel

Mahin Heravi - One of the best experts on this subject based on the ideXlab platform.

  • METABOLIC AND SKELETAL EFFECTS OF LOW AND HIGH DOSES OF Calcium Acetate IN PATIENTS WITH PRETERMINAL CHRONIC RENAL FAILURE
    American Journal of Nephrology, 2002
    Co-Authors: Kenneth R. Phelps, Marc Stern, Alice Slingerland, Mahin Heravi, David S. Strogatz, Syed S. Haqqie
    Abstract:

    Background: Secondary hyperparathyroidism commonly evolves, as the glomerular filtration rate falls. The metabolic and skeletal effects of a possible remedy, Calcium Acetate, have n

  • Metabolic and skeletal effects of low and high doses of Calcium Acetate in patients with preterminal chronic renal failure.
    American journal of nephrology, 2002
    Co-Authors: Kenneth R. Phelps, Marc Stern, Alice Slingerland, Mahin Heravi, David S. Strogatz, Syed S. Haqqie
    Abstract:

    Secondary hyperparathyroidism commonly evolves, as the glomerular filtration rate falls. The metabolic and skeletal effects of a possible remedy, Calcium Acetate, have not been studied in patients with preterminal chronic renal failure. Men with a mean creatinine clearance of approximately 30 ml/min took Calcium Acetate for 24 weeks at doses which provided 507 or 1,521 mg Calcium/day with meals. Metabolic determinations were made at intervals of 4-8 weeks, and the bone mineral density (BMD) was measured at the beginning and at the end of the trial. The low-dose regimen produced no metabolic or skeletal effect. In subjects prescribed the high-dose regimen, the 24-hour urine phosphorus excretion fell from 0.53 mg/mg creatinine to values ranging from 0.34 to 0.41 mg/mg creatinine. The theoretical phosphorus threshold concentration rose by a maximum of 38.6%, and the serum phosphorus concentration did not change. The mean serum Calcium concentration rose by a maximum of 7.2%. The mean fractional changes in parathyroid hormone and 1,25-dihydroxyvitamin D concentrations ranged from -27.0 to -39.6% and from -5.0 to -20.3%, respectively. The BMD increased at L1, L3, and L4. Calcium Acetate prescribed to deliver 1,521 mg Calcium/day with meals reduced parathyroid hormone and 1,25-dihydroxyvitamin D concentrations and increased lumbar BMD in men with preterminal chronic renal failure. Copyright 2002 S. Karger AG, Basel